Prospective multi-center study for quantification of chemotherapies and CTX-related direct medication costs avoided by use of biomarkers uPA and PAI-1in primary breast cancer

Breast

Volumn 22, Issue 4, 2013, Pages 436-443

  Jacobs, Volker R ^a   Augustin, Doris ^b   Wischnik, Arthur ^c   Kiechle, Marion ^d   Höss, Cornelia ^e   Steinkohl, Oliver ^f   Rack, Brigitte ^g   Kapitza, Thomas ^h   Krase, Peter ⁱ  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b Klinikum Deggendorf   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e Kreisklinikum Ebersberg ^*  (Germany)

^f Klinikum Dritter Orden   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h Sachverstaendigenbüro Kapitza   (Germany)

ⁱ Vorstandsvorsitzender der AOK Bayern   (Germany)

Author keywords

Biomarker; Breast cancer; Clinical cost effectiveness analysis; Costs; Economics; Prevention of chemotherapy; Quality of life

Indexed keywords

AMEND; APREPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; MESNA; METOCLOPRAMIDE; ONDANSETRON; PANTOPRAZOLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL DECISION MAKING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INVESTMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE;

EID: 84879781104     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.04.009     Document Type: Article

References (31)

1. Harbeck N., Dettmar P., Thomssen C., Henselmann B., Kuhn W., Ulm K., et al. Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 1998, 18(3C):2187-2197.
2. Harbeck N., Thomssen C., Berger U., Ulm K., Kates R.E., Höfler H., et al. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse. Breast Cancer Res Treat 1999, 54(2):147-157.
3. Janicke F., Prechtl A., Thomssen C., Harbeck N., Meisner C., Untch M., et al. Randomized adjuvant chemotherapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. JNatl Cancer Inst 2001, 93(12):913-920.
4. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. JNatl Cancer Inst 2002, 94(2):116-128.
5. Harbeck N., Kates R.E., Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. JClin Oncol 2002, 20(4):1000-1007.
6. Zemzoum I., Kates R.E., Ross J.S., Dettmar P., Dutta M., Henrichs C., et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. JClin Oncol 2003, 21(6):122-128.
7. Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993, 24(3):195-208.
8. Rosenquist C., Thorpe S.M., Danø K., Grøndahl-Hansen J. Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Res Treat 1993, 28(3):223-229.
9. Schmitt M., Harbeck N., Brünner N., Jänicke F., Meisner C., Mühlenweg B., et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2011, 11(6):617-634.
10. Schmitt M., Mengele K., Napieralski R., Magdolen V., Reuning U., Gkazepis A., et al. Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn 2010, 10(8):1051-1067.
11. Kantelhardt E.J., Vetter M., Schmidt M., Veyret C., Augustin D., Hanf V., et al. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel. BMC Cancer 2011, 11:140.
12. German Society of Senology (DGS) Interdisciplinary S3 guidelines for the diagnosis, treatment and follow-up care of breast cancer [accessed 04.02.13]. http://www.senologie.org/leitlinien.php.
13. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25(33):5287-5312.
14. AGO Kommission Mamma Breast cancer guidelines [accessed 04.02.13]. http://www.ago-online.de/de/fuer-mediziner/leitlinien/mamma/march-2012/.
15. Harbeck N., Schmitt M., Meisner C., Friedel C., Untch M., Schmid M., et al. Ten-year analysis of the prospective multicenter Chemo-N0 trial validates ASCO-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer 2013, 49(8):1825-1835. for the Chemo-N0 Study Group.
16. Eljuga D., Razumovic J.J., Bulic K., Petrovecki M., Draca N., Bulic S.O. Prognostic importance of PAI-1 in node negative breast cancer patients-results after 10 years of follow up. Pathol Res Pract 2011, 207(5):290-294.
17. Borstnar S., Sadikov A., Mozina B., Cufer T. High levels of uPA and PAI-1 predicta good response to anthracyclines. Breast Cancer Res Treat 2010, 121(3):615-624.
18. Pritchard K.I. High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res Treat 2010, 121(3):625-626.
19. Williams C., Brunskill S., Altman D., Briggs A., Campbell H., Clarke M., et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technol Assess September 2006, 10(34).
20. Yang M., Rajan S., Issa A.M. Cost effectiveness of gene expression profiling for early stage breast cancer: a decision-analytic model. Cancer 2012, 118(20):5163-5170.
21. Deutsche Gesellschaft für Senologie (DGS) Zertifizierungsrichtlinien [accessed 04.02.13]. http://www.senologie.org/brustzentren/brust_zertifirichtl.php.
22. Allgemeine Ortskrankenkasse (AOK) Yearly number of breast cancer diagnosis. From: Weisse Liste [accessed 04.02.13]. http://weisse-liste.krankenhaus.aok.de/.
23. AOK Bayern Health Care Fund [accessed 04.02.13]. http://www.aok.de/bayern/die-aok/wir-ueber-uns-daten-und-fakten-24825.php.
24. Dubois-Formula [accessed 04.02.13]. http://flexikon.doccheck.com/Dubois-Formel.
25. Dubois D., Dubois E.F. Aformula to estimate the approximate surface area if height and weight be known. Arch Int Med Chicago 1916, 17:863-871.
26. Rote Liste (German Pharmaceutical Price Index) [accessed 04.02.13]. http://www.rote-liste.de/.
27. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47(1):8-32.
28. Cooper K.L., Madan J., Whyte S., Stevenson M.D., Akehurst R.L. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.
29. Hershman D.L., Wilde E.T., Wright J.D., Buono D.L., Kalinsky K., Malin J.L., et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. JClin Oncol 2012, 30:806-812.
30. American Diagnostica [accessed 04.02.13]. http://www.femtelle.de/en/.
31. Bavarian Data Protection Law [accessed 04.02.13]. http://byds.juris.de/byds/009_1.1_DSG_BY_1993_rahmen.html.